Aadi Biosciences Inc is a biotechnology company focused on developing and commercializing innovative therapies for patients with cancer
The company specializes in creating targeted treatments that aim to enhance the efficacy and safety of cancer care, particularly for individuals with difficult-to-treat tumors. By leveraging advanced drug development techniques and a deep understanding of cancer biology, Aadi Biosciences strives to address unmet medical needs and improve outcomes for patients battling various forms of cancer. Through its research and clinical trials, the company is dedicated to delivering comprehensive solutions that ultimately aim to transform the landscape of oncology treatment.
Aadi Bioscience halts its PRECISION1 trial of nab-sirolimus in solid tumors with TSC1/TSC2 mutations due to insufficient efficacy. The company will focus on maximizing Fyarro sales, pausing new enrollments in other trials, and reducing its R&D workforce to extend cash runway into late 2026.
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQSGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Shares of BioVie Inc. (NASDAQBIVI) fell sharply in today’s pre-market trading after the company reported pricing of public offering. BioVie shares dipped 41.8% to $1.10 in pre-market trading Here are some other stocks moving in pre-market trading.
Shares of Bitdeer Technologies Group (NASDAQBTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.
Friday, Aadi Bioscience Inc (NASDAQAADI) released results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial of nab-sirolimus in patients with
Shares of Quanex Building Products Corporation (NYSENX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7% to $30.95 on Friday.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 60 points on Friday. The Dow traded up 0.11% to 37,288.04 while the NASDAQ rose 0.45% to 14,827.63. The S&P 500 also rose, gaining, 0.06% to 4,722.55.
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 75 points on Friday. The Dow traded down 0.20% to 37,173.96 while the NASDAQ rose 0.31% to 14,806.71. The S&P 500 also fell, dropping, 0.19% to 4,710.37.
Aadi Bioscience Inc (NASDAQAADI) shares are trading lower after the company released results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial of nab-sirolimus in patients with TSC1 or TSC2
Shares of Getaround, Inc. (NYSEGETR) rose sharply in pre-market trading after the company reported a year-over-year increase in third-quarter financial results.
